Free Webinar, Derm Clinical Updates: Keeping Up with COVID-19


Enjoy our archived discussion between 4 experts on how their specialty is most affected by the pandemic.

At a time when discovery and federal decision is influencing millions of at-risk lives in any moment, platforms are needed to deliver insight promptly and accessibly.

Clinical webinars, at the height of the coronavirus 2019 (COVID-19) pandemic, has become one of the greatest means by which experts are continuing topline discussion.

Last week, HCPLive® along with sister publication Dermatology Times hosted a free online webinar titled, “Derm Clinical Updates: Keeping Up with COVID-19.”

The interactive, news-driven discussion for caregivers in dermatology included the following speakers:

  • Brad Glick, DO, FAAD, Board-Certified Dermatologist and Dermatologic Surgeon with the Glick Skin Institute
  • Joel Gelfand, MD, MSCE, Professor of Dermatology and Epidemiology at the University of Pennsylvania’s Perelman School of Medicine
  • M. Laurin Council, MD, Associate Professor of Dermatology at Washington University School of Medicine
  • Adam Friedman, MD, Professor & Interim Chair of Dermatology at The George Washington University School of Medicine and Health Sciences

In discussing a bevy COVID-19 topics pertinent to their specialty— including management of immunocompromised patients, maintaining biologic care, telemedicine, what dermatologists should know from the most recent COVID-19 clinical trials, and more—the experts fielded lingering questions from hundreds of colleagues and shared opinion on the latest developments to the pandemic.

Now, the discussion is available to everyone.

Please enjoy our archived presentation of the webinar, and stay tuned for more coverage and insight from both our editorial team and featured panelists later this week.

Related Videos
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
© 2024 MJH Life Sciences

All rights reserved.